The research program in our lab is focused on identifying genetic and environmental factors that contribute to the development of cancer. Our research group takes advantage of methods in molecular and genetic epidemiology, concentrating on population-based epidemiologic studies for the discovery of genes and variants conferring susceptibility to cancer. A major focus of our lab is directed towards the genetic and molecular characterization of the epidemiology colorectal cancer. Dr. Gruber also serves as the Director of the Cancer Genetics Clinic and the co-director of Biomedical Prevention for the University of Michigan Comprehensive Cancer Center with Dr. Dean Brenner.
1984 B. A., University of Pennsylvania (English/Biology)
1986 Masters of Public Health, Yale University School of Medicine (Distinction)
1988 Ph.D., Yale University Graduate School (Epidemiology)
1992 M.D., University of Pennsylvania
1992-1993 Intern, University of Pennsylvania (Internal Medicine)
1993-1994 Resident, University of Pennsylvania (Internal Medicine)
1994-1997 Fellow, Johns Hopkins Hospital (Medical Oncology)
1997-1999 Fellow, University of Michigan (Clinical Medical Genetics)
Honors and Awards
1986 Distinction, Yale University
1986-1988 NIH Cancer Training Grant
1989-1992 Penn Medical Scholar
1991-1992 Four Schools Physician Scientist Program, Sabbatical: Molecular Biology of Cancer
1992 Alfred Stengel Memorial Prize
1994 Penn Pearls Teaching Award
1994 Humaneness in Medicine, Philadelphia County Medical Society
1994-1995 American Cancer Society, Fellowship in Clinical Oncology
1995-1996 Oncology Chemotherapy, Immunology, and Biology Training Grant Recipient
1997 Berlex Oncology Foundation, Genetics in Oncology Fellow
2002 Jerome Conn Award for Excellence in Research
2003 American Society of Clinical Investigation, Member
Cooney KA, Gruber SB. Hyperglycemia, obesity, and cancer risks on the horizon. JAMA, 293:235-236, 2005.
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. New Engl J Med, 2005. 352(21): 2238-9.
Niell BL, Rennert G., Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. JNCI, 96:15-21.
Amend KL, Tomsho LP, Bonner JD, Johnson TM, Berwick M, Elder JT, Gruber SB (2004) EGF gene polymorphism and the risk of incident primary melanoma. Cancer Research, 64:2668-2672.
Lipkin SM, Rozek LS, Rennert G, Yang W, Chieh P, Chen J, Hacia J, Hunt N, Shin B, Fodor S, Kokoris M, Greenson JK, Fearon ER, Lynch HT, Collins FS, Gruber SB (2004) The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nature Genetics, 39:694-699.
Rozek LS, Lipkin SM, Fearon ER, Hanash S, Giordano TJ, Kuick R, Misek DE, Taylor JMG, Greenson JK, Rennert G, Gruber SB (2005) CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Research, 65:5488-92.
Douglas JA, Gruber SB, Meister KA, Bonner JD, Watson P, Krush AJ, Lynch HT (2005) History and Molecular Genetics of Hereditary Non-Polyposis Colorectal Cancer in Family G – A Century Later. JAMA, 294(17):2195-202.
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer, 5(12):930-42.
Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-73.
Please contact Dr. Gruber for information regarding current research projects.
Additional Lab Links
Victor Moreno, MD, PhD
Post Doctoral Fellows:
Kirsten Kangelaris, MD
Leon Raskin, PhD
Laura Rozek, PhD, MS
Shu Chen Huang